Paclitaxel Delivery to the Brain for Glioblastoma Treatment

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Brain tumors, including glioblastoma, present significant therapeutic challenges due to the blood-brain barrier.
• Effective drug delivery to the brain is crucial for improving treatment outcomes.
• Paclitaxel is a potent chemotherapeutic agent with limited efficacy against brain tumors when administered conventionally.

Purpose of the Study:

• To develop and evaluate paclitaxel-loaded poly(lactide-glycolide) (PLGA) nanoparticles for brain tumor treatment.
• To assess the efficacy and biodistribution of PLGA nanoparticles administered via intranasal and intravenous routes.
• To compare the anti-proliferative effects of nanoparticle-delivered paclitaxel with free paclitaxel.

Main Methods:

• Poly(lactide-glycolide) (PLGA) nanoparticles were formulated to encapsulate paclitaxel at a 10% w/w concentration.
• The developed nanoparticles exhibited a particle size of 216 nm.
• Male Sprague-Dawley rats received intranasal or intravenous administration of paclitaxel-loaded PLGA nanoparticles at a dose of 5 mg/kg.

Main Results:

• Paclitaxel-loaded PLGA nanoparticles demonstrated significant accumulation in brain tissue, liver, and kidney following both intranasal and intravenous administration.
• No signs of toxicity were observed in the rats after nanoparticle administration.
• The anti-proliferative efficacy of paclitaxel delivered via PLGA nanoparticles was comparable to that of free paclitaxel against glioblastoma cells.

Conclusions:

• Paclitaxel-loaded PLGA nanoparticles represent a viable drug delivery system for brain tumors.
• Both intranasal and intravenous routes are effective for delivering paclitaxel to the brain with PLGA nanoparticles.
• This nanoparticle formulation offers a potentially safer and more effective strategy for brain tumor chemotherapy.